Ocugen (BUL:2H51) - Prezzo delle azioni, notizie e analisi

2H51 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.

Informazioni sull'azienda

2H51 analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Le azioni sono altamente illiquide

Ha meno di 1 anno di pista di cassa

Gli azionisti sono stati diluiti nell'ultimo anno

+ 1 più rischio

Ocugen, Inc. Concorrenti

Instil Bio

NasdaqCM:TIL

US$202.0m

Design Therapeutics

NasdaqGS:DSGN

US$308.0m

Acumen Pharmaceuticals

NasdaqGS:ABOS

US$174.2m

Corbus Pharmaceuticals Holdings

NasdaqCM:CRBP

US$196.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Ocugen
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.35
Massimo di 52 settimane	US$0.35
Minimo di 52 settimane	US$0.35
Beta	3.56
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	-65.59%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-93.48%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2H51	BG Biotechs	BG Mercato
7D	0%	0%	0%
1Y	-65.6%	0%	0%

Ritorno vs Industria: 2H51 ha avuto una performance inferiore rispetto al BG Biotechs che ha registrato un rendimento 0.2 % nell'ultimo anno.

Rendimento vs Mercato: 2H51 ha avuto una performance inferiore al mercato BG che ha registrato un rendimento 13.3 % nell'ultimo anno.

Volatilità dei prezzi

Is 2H51's price volatile compared to industry and market?
2H51 volatility
2H51 Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BG Market	0%
10% least volatile stocks in BG Market	0%

Prezzo delle azioni stabile: 2H51 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 2H51 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	84	Shankar Musunuri	www.ocugen.com

Ocugen, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Ocugen con la sua capitalizzazione di mercato?
2H51 statistiche fondamentali
Capitalizzazione di mercato	€234.13m
Guadagni(TTM)	-€69.63m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-3.4x

Rapporto P/E

2H51 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2H51 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$47.28m
Profitto lordo	-US$47.28m
Altre spese	US$28.24m
Guadagni	-US$75.52m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.29
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	4.7%

Come si è comportato 2H51 nel lungo periodo?

Vedi performance storica e confronto

2H51 Panoramica delle azioni

Premi

Analisi del rischio

Ocugen, Inc. Concorrenti

NasdaqCM:TIL

US$202.0m

NasdaqGS:DSGN

US$308.0m

NasdaqGS:ABOS

US$174.2m

NasdaqCM:CRBP

US$196.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Recent updates

Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)